Global Diabetic Neuropathic Pain Drug Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Diabetic Neuropathic Pain Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Diabetic Neuropathic Pain Drug Industry Forecast” looks at past sales and reviews total world Diabetic Neuropathic Pain Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Diabetic Neuropathic Pain Drug sales for 2025 through 2031. With Diabetic Neuropathic Pain Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Neuropathic Pain Drug industry.
This Insight Report provides a comprehensive analysis of the global Diabetic Neuropathic Pain Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Neuropathic Pain Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Neuropathic Pain Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Neuropathic Pain Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Neuropathic Pain Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Neuropathic Pain Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Diabetic Neuropathic Pain Drug market?
What factors are driving Diabetic Neuropathic Pain Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Diabetic Neuropathic Pain Drug market opportunities vary by end market size?
How does Diabetic Neuropathic Pain Drug break out by Type, by Application?
The global Diabetic Neuropathic Pain Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Diabetic Neuropathic Pain Drug Industry Forecast” looks at past sales and reviews total world Diabetic Neuropathic Pain Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Diabetic Neuropathic Pain Drug sales for 2025 through 2031. With Diabetic Neuropathic Pain Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Neuropathic Pain Drug industry.
This Insight Report provides a comprehensive analysis of the global Diabetic Neuropathic Pain Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Neuropathic Pain Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Neuropathic Pain Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Neuropathic Pain Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Neuropathic Pain Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Neuropathic Pain Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- AZD-5213
- Clonidine Hydrochloride
- Duloxetine Hydrochloride DR
- E-52862
- Filgrastim
- GERPOOI
- GRC-17536
- Others
- Clinic
- Hospital
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma Inc.
- AstraZeneca Plc
- BioDelivery Sciences International, Inc.
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company, Limited
- Dong-A Socio Group
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Hydra Biosciences, Inc.
- Immune Pharmaceuticals Inc.
- Laboratorios Del Dr. Esteve S.A.
- Lohocla Research Corporation
- Mertiva AB
- Novaremed
- Pharmaleads
- RAPID Pharmaceuticals AG
- Relmada Therapeutics, Inc.
- Sphaera Pharma Pvt. Ltd.
- Theravasc, Inc.
What is the 10-year outlook for the global Diabetic Neuropathic Pain Drug market?
What factors are driving Diabetic Neuropathic Pain Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Diabetic Neuropathic Pain Drug market opportunities vary by end market size?
How does Diabetic Neuropathic Pain Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Diabetic Neuropathic Pain Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Diabetic Neuropathic Pain Drug by Country/Region, 2020, 2024 & 2031
2.2 Diabetic Neuropathic Pain Drug Segment by Type
2.2.1 AZD-5213
2.2.2 Clonidine Hydrochloride
2.2.3 Duloxetine Hydrochloride DR
2.2.4 E-52862
2.2.5 Filgrastim
2.2.6 GERPOOI
2.2.7 GRC-17536
2.2.8 Others
2.3 Diabetic Neuropathic Pain Drug Sales by Type
2.3.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Diabetic Neuropathic Pain Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Diabetic Neuropathic Pain Drug Sale Price by Type (2020-2025)
2.4 Diabetic Neuropathic Pain Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Diabetic Neuropathic Pain Drug Sales by Application
2.5.1 Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Diabetic Neuropathic Pain Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Diabetic Neuropathic Pain Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Diabetic Neuropathic Pain Drug Breakdown Data by Company
3.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Company (2020-2025)
3.1.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Company (2020-2025)
3.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Company (2020-2025)
3.2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company (2020-2025)
3.3 Global Diabetic Neuropathic Pain Drug Sale Price by Company
3.4 Key Manufacturers Diabetic Neuropathic Pain Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Diabetic Neuropathic Pain Drug Product Location Distribution
3.4.2 Players Diabetic Neuropathic Pain Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DIABETIC NEUROPATHIC PAIN DRUG BY GEOGRAPHIC REGION
4.1 World Historic Diabetic Neuropathic Pain Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Diabetic Neuropathic Pain Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Diabetic Neuropathic Pain Drug Sales Growth
4.4 APAC Diabetic Neuropathic Pain Drug Sales Growth
4.5 Europe Diabetic Neuropathic Pain Drug Sales Growth
4.6 Middle East & Africa Diabetic Neuropathic Pain Drug Sales Growth
5 AMERICAS
5.1 Americas Diabetic Neuropathic Pain Drug Sales by Country
5.1.1 Americas Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
5.1.2 Americas Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
5.2 Americas Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
5.3 Americas Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diabetic Neuropathic Pain Drug Sales by Region
6.1.1 APAC Diabetic Neuropathic Pain Drug Sales by Region (2020-2025)
6.1.2 APAC Diabetic Neuropathic Pain Drug Revenue by Region (2020-2025)
6.2 APAC Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
6.3 APAC Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Diabetic Neuropathic Pain Drug by Country
7.1.1 Europe Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
7.1.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
7.2 Europe Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
7.3 Europe Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Diabetic Neuropathic Pain Drug by Country
8.1.1 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Diabetic Neuropathic Pain Drug
10.3 Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
10.4 Industry Chain Structure of Diabetic Neuropathic Pain Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Diabetic Neuropathic Pain Drug Distributors
11.3 Diabetic Neuropathic Pain Drug Customer
12 WORLD FORECAST REVIEW FOR DIABETIC NEUROPATHIC PAIN DRUG BY GEOGRAPHIC REGION
12.1 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Region
12.1.1 Global Diabetic Neuropathic Pain Drug Forecast by Region (2026-2031)
12.1.2 Global Diabetic Neuropathic Pain Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Diabetic Neuropathic Pain Drug Forecast by Type (2026-2031)
12.7 Global Diabetic Neuropathic Pain Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Information
13.1.2 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Astellas Pharma Inc. Main Business Overview
13.1.5 Astellas Pharma Inc. Latest Developments
13.2 AstraZeneca Plc
13.2.1 AstraZeneca Plc Company Information
13.2.2 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Plc Main Business Overview
13.2.5 AstraZeneca Plc Latest Developments
13.3 BioDelivery Sciences International, Inc.
13.3.1 BioDelivery Sciences International, Inc. Company Information
13.3.2 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 BioDelivery Sciences International, Inc. Main Business Overview
13.3.5 BioDelivery Sciences International, Inc. Latest Developments
13.4 Boehringer Ingelheim GmbH
13.4.1 Boehringer Ingelheim GmbH Company Information
13.4.2 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Boehringer Ingelheim GmbH Main Business Overview
13.4.5 Boehringer Ingelheim GmbH Latest Developments
13.5 Daiichi Sankyo Company, Limited
13.5.1 Daiichi Sankyo Company, Limited Company Information
13.5.2 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Daiichi Sankyo Company, Limited Main Business Overview
13.5.5 Daiichi Sankyo Company, Limited Latest Developments
13.6 Dong-A Socio Group
13.6.1 Dong-A Socio Group Company Information
13.6.2 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dong-A Socio Group Main Business Overview
13.6.5 Dong-A Socio Group Latest Developments
13.7 Eli Lilly and Company
13.7.1 Eli Lilly and Company Company Information
13.7.2 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Eli Lilly and Company Main Business Overview
13.7.5 Eli Lilly and Company Latest Developments
13.8 Glenmark Pharmaceuticals Ltd.
13.8.1 Glenmark Pharmaceuticals Ltd. Company Information
13.8.2 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Glenmark Pharmaceuticals Ltd. Main Business Overview
13.8.5 Glenmark Pharmaceuticals Ltd. Latest Developments
13.9 Hydra Biosciences, Inc.
13.9.1 Hydra Biosciences, Inc. Company Information
13.9.2 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Hydra Biosciences, Inc. Main Business Overview
13.9.5 Hydra Biosciences, Inc. Latest Developments
13.10 Immune Pharmaceuticals Inc.
13.10.1 Immune Pharmaceuticals Inc. Company Information
13.10.2 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Immune Pharmaceuticals Inc. Main Business Overview
13.10.5 Immune Pharmaceuticals Inc. Latest Developments
13.11 Laboratorios Del Dr. Esteve S.A.
13.11.1 Laboratorios Del Dr. Esteve S.A. Company Information
13.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Laboratorios Del Dr. Esteve S.A. Main Business Overview
13.11.5 Laboratorios Del Dr. Esteve S.A. Latest Developments
13.12 Lohocla Research Corporation
13.12.1 Lohocla Research Corporation Company Information
13.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Lohocla Research Corporation Main Business Overview
13.12.5 Lohocla Research Corporation Latest Developments
13.13 Mertiva AB
13.13.1 Mertiva AB Company Information
13.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Mertiva AB Main Business Overview
13.13.5 Mertiva AB Latest Developments
13.14 Novaremed
13.14.1 Novaremed Company Information
13.14.2 Novaremed Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Novaremed Main Business Overview
13.14.5 Novaremed Latest Developments
13.15 Pharmaleads
13.15.1 Pharmaleads Company Information
13.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Pharmaleads Main Business Overview
13.15.5 Pharmaleads Latest Developments
13.16 RAPID Pharmaceuticals AG
13.16.1 RAPID Pharmaceuticals AG Company Information
13.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 RAPID Pharmaceuticals AG Main Business Overview
13.16.5 RAPID Pharmaceuticals AG Latest Developments
13.17 Relmada Therapeutics, Inc.
13.17.1 Relmada Therapeutics, Inc. Company Information
13.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Relmada Therapeutics, Inc. Main Business Overview
13.17.5 Relmada Therapeutics, Inc. Latest Developments
13.18 Sphaera Pharma Pvt. Ltd.
13.18.1 Sphaera Pharma Pvt. Ltd. Company Information
13.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Sphaera Pharma Pvt. Ltd. Main Business Overview
13.18.5 Sphaera Pharma Pvt. Ltd. Latest Developments
13.19 Theravasc, Inc.
13.19.1 Theravasc, Inc. Company Information
13.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Theravasc, Inc. Main Business Overview
13.19.5 Theravasc, Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Diabetic Neuropathic Pain Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Diabetic Neuropathic Pain Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of AZD-5213
Table 4. Major Players of Clonidine Hydrochloride
Table 5. Major Players of Duloxetine Hydrochloride DR
Table 6. Major Players of E-52862
Table 7. Major Players ofFilgrastim
Table 8. Major Players of GERPOOI
Table 9. Major Players of GRC-17536
Table 10. Major Players of Others
Table 11. Global Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 12. Global Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Table 13. Global Diabetic Neuropathic Pain Drug Revenue byType (2020-2025) & ($ million)
Table 14. Global Diabetic Neuropathic Pain Drug Revenue Market Share byType (2020-2025)
Table 15. Global Diabetic Neuropathic Pain Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 16. Global Diabetic Neuropathic Pain Drug Sale by Application (2020-2025) & (K Pcs)
Table 17. Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2020-2025)
Table 18. Global Diabetic Neuropathic Pain Drug Revenue by Application (2020-2025) & ($ million)
Table 19. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2020-2025)
Table 20. Global Diabetic Neuropathic Pain Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 21. Global Diabetic Neuropathic Pain Drug Sales by Company (2020-2025) & (K Pcs)
Table 22. Global Diabetic Neuropathic Pain Drug Sales Market Share by Company (2020-2025)
Table 23. Global Diabetic Neuropathic Pain Drug Revenue by Company (2020-2025) & ($ millions)
Table 24. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company (2020-2025)
Table 25. Global Diabetic Neuropathic Pain Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 26. Key Manufacturers Diabetic Neuropathic Pain Drug Producing Area Distribution and Sales Area
Table 27. Players Diabetic Neuropathic Pain Drug Products Offered
Table 28. Diabetic Neuropathic Pain Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Diabetic Neuropathic Pain Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 32. Global Diabetic Neuropathic Pain Drug Sales Market Share Geographic Region (2020-2025)
Table 33. Global Diabetic Neuropathic Pain Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 34. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Geographic Region (2020-2025)
Table 35. Global Diabetic Neuropathic Pain Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 36. Global Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2020-2025)
Table 37. Global Diabetic Neuropathic Pain Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 38. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Country/Region (2020-2025)
Table 39. Americas Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 40. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Country (2020-2025)
Table 41. Americas Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025) & ($ millions)
Table 42. Americas Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 43. Americas Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 44. APAC Diabetic Neuropathic Pain Drug Sales by Region (2020-2025) & (K Pcs)
Table 45. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Region (2020-2025)
Table 46. APAC Diabetic Neuropathic Pain Drug Revenue by Region (2020-2025) & ($ millions)
Table 47. APAC Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 48. APAC Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Europe Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025) & ($ millions)
Table 51. Europe Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Europe Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Table 55. Middle East & Africa Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 56. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 57. Key Market Drivers & Growth Opportunities of Diabetic Neuropathic Pain Drug
Table 58. Key Market Challenges & Risks of Diabetic Neuropathic Pain Drug
Table 59. Key IndustryTrends of Diabetic Neuropathic Pain Drug
Table 60. Diabetic Neuropathic Pain Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Diabetic Neuropathic Pain Drug Distributors List
Table 63. Diabetic Neuropathic Pain Drug Customer List
Table 64. Global Diabetic Neuropathic Pain Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. Global Diabetic Neuropathic Pain Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Americas Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Americas Diabetic Neuropathic Pain Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. APAC Diabetic Neuropathic Pain Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 69. APAC Diabetic Neuropathic Pain Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 70. Europe Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 71. Europe Diabetic Neuropathic Pain Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 72. Middle East & Africa Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 73. Middle East & Africa Diabetic Neuropathic Pain Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 74. Global Diabetic Neuropathic Pain Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 75. Global Diabetic Neuropathic Pain Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 76. Global Diabetic Neuropathic Pain Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 77. Global Diabetic Neuropathic Pain Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 78. Astellas Pharma Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 80. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 81. Astellas Pharma Inc. Main Business
Table 82. Astellas Pharma Inc. Latest Developments
Table 83. AstraZeneca Plc Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 85. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 86. AstraZeneca Plc Main Business
Table 87. AstraZeneca Plc Latest Developments
Table 88. BioDelivery Sciences International, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 90. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 91. BioDelivery Sciences International, Inc. Main Business
Table 92. BioDelivery Sciences International, Inc. Latest Developments
Table 93. Boehringer Ingelheim GmbH Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 95. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 96. Boehringer Ingelheim GmbH Main Business
Table 97. Boehringer Ingelheim GmbH Latest Developments
Table 98. Daiichi Sankyo Company, Limited Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 100. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 101. Daiichi Sankyo Company, Limited Main Business
Table 102. Daiichi Sankyo Company, Limited Latest Developments
Table 103. Dong-A Socio Group Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 105. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 106. Dong-A Socio Group Main Business
Table 107. Dong-A Socio Group Latest Developments
Table 108. Eli Lilly and Company Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 110. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 111. Eli Lilly and Company Main Business
Table 112. Eli Lilly and Company Latest Developments
Table 113. Glenmark Pharmaceuticals Ltd. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 115. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 116. Glenmark Pharmaceuticals Ltd. Main Business
Table 117. Glenmark Pharmaceuticals Ltd. Latest Developments
Table 118. Hydra Biosciences, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 120. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 121. Hydra Biosciences, Inc. Main Business
Table 122. Hydra Biosciences, Inc. Latest Developments
Table 123. Immune Pharmaceuticals Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 125. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 126. Immune Pharmaceuticals Inc. Main Business
Table 127. Immune Pharmaceuticals Inc. Latest Developments
Table 128. Laboratorios Del Dr. Esteve S.A. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 130. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 131. Laboratorios Del Dr. Esteve S.A. Main Business
Table 132. Laboratorios Del Dr. Esteve S.A. Latest Developments
Table 133. Lohocla Research Corporation Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 135. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 136. Lohocla Research Corporation Main Business
Table 137. Lohocla Research Corporation Latest Developments
Table 138. Mertiva AB Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 139. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 140. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 141. Mertiva AB Main Business
Table 142. Mertiva AB Latest Developments
Table 143. Novaremed Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 144. Novaremed Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 145. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 146. Novaremed Main Business
Table 147. Novaremed Latest Developments
Table 148. Pharmaleads Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 149. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 150. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 151. Pharmaleads Main Business
Table 152. Pharmaleads Latest Developments
Table 153. RAPID Pharmaceuticals AG Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 154. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 155. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 156. RAPID Pharmaceuticals AG Main Business
Table 157. RAPID Pharmaceuticals AG Latest Developments
Table 158. RelmadaTherapeutics, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 159. RelmadaTherapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 160. RelmadaTherapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 161. RelmadaTherapeutics, Inc. Main Business
Table 162. RelmadaTherapeutics, Inc. Latest Developments
Table 163. Sphaera Pharma Pvt. Ltd. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 164. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 165. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 166. Sphaera Pharma Pvt. Ltd. Main Business
Table 167. Sphaera Pharma Pvt. Ltd. Latest Developments
Table 168.Theravasc, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 169.Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 170.Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 171.Theravasc, Inc. Main Business
Table 172.Theravasc, Inc. Latest Developments
LIST OFFIGURES
Figure 1. Picture of Diabetic Neuropathic Pain Drug
Figure 2. Diabetic Neuropathic Pain Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Diabetic Neuropathic Pain Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Diabetic Neuropathic Pain Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Diabetic Neuropathic Pain Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2024)
Figure 10. Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of AZD-5213
Figure 12. Product Picture of Clonidine Hydrochloride
Figure 13. Product Picture of Duloxetine Hydrochloride DR
Figure 14. Product Picture of E-52862
Figure 15. Product Picture ofFilgrastim
Figure 16. Product Picture of GERPOOI
Figure 17. Product Picture of GRC-17536
Figure 18. Product Picture of Others
Figure 19. Global Diabetic Neuropathic Pain Drug Sales Market Share byType in 2025
Figure 20. Global Diabetic Neuropathic Pain Drug Revenue Market Share byType (2020-2025)
Figure 21. Diabetic Neuropathic Pain Drug Consumed in Clinic
Figure 22. Global Diabetic Neuropathic Pain Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Diabetic Neuropathic Pain Drug Consumed in Hospital
Figure 24. Global Diabetic Neuropathic Pain Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 25. Diabetic Neuropathic Pain Drug Consumed in Others
Figure 26. Global Diabetic Neuropathic Pain Drug Market: Others (2020-2025) & (K Pcs)
Figure 27. Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2024)
Figure 28. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application in 2025
Figure 29. Diabetic Neuropathic Pain Drug Sales by Company in 2025 (K Pcs)
Figure 30. Global Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2025
Figure 31. Diabetic Neuropathic Pain Drug Revenue by Company in 2025 ($ millions)
Figure 32. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company in 2025
Figure 33. Global Diabetic Neuropathic Pain Drug Sales Market Share by Geographic Region (2020-2025)
Figure 34. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Geographic Region in 2025
Figure 35. Americas Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 36. Americas Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 37. APAC Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 38. APAC Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 39. Europe Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 40. Europe Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 41. Middle East & Africa Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 42. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 43. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2025
Figure 44. Americas Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Figure 45. Americas Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 46. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 47. United States Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Canada Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. Mexico Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Brazil Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2025
Figure 52. APAC Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2020-2025)
Figure 53. APAC Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 54. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 55. China Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Japan Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. South Korea Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Southeast Asia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. India Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Australia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. ChinaTaiwan Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2025
Figure 63. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Figure 64. Europe Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 65. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 66. Germany Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 67.France Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. UK Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Italy Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Russia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2020-2025)
Figure 72. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 73. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 74. Egypt Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. South Africa Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Israel Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 77.Turkey Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 78. GCC Countries Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Diabetic Neuropathic Pain Drug in 2025
Figure 80. Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
Figure 81. Industry Chain Structure of Diabetic Neuropathic Pain Drug
Figure 82. Channels of Distribution
Figure 83. Global Diabetic Neuropathic Pain Drug Sales MarketForecast by Region (2026-2031)
Figure 84. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 85. Global Diabetic Neuropathic Pain Drug Sales Market ShareForecast byType (2026-2031)
Figure 86. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast byType (2026-2031)
Figure 87. Global Diabetic Neuropathic Pain Drug Sales Market ShareForecast by Application (2026-2031)
Figure 88. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Diabetic Neuropathic Pain Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Diabetic Neuropathic Pain Drug by Country/Region, 2020, 2024 & 2031
2.2 Diabetic Neuropathic Pain Drug Segment by Type
2.2.1 AZD-5213
2.2.2 Clonidine Hydrochloride
2.2.3 Duloxetine Hydrochloride DR
2.2.4 E-52862
2.2.5 Filgrastim
2.2.6 GERPOOI
2.2.7 GRC-17536
2.2.8 Others
2.3 Diabetic Neuropathic Pain Drug Sales by Type
2.3.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Diabetic Neuropathic Pain Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Diabetic Neuropathic Pain Drug Sale Price by Type (2020-2025)
2.4 Diabetic Neuropathic Pain Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Diabetic Neuropathic Pain Drug Sales by Application
2.5.1 Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Diabetic Neuropathic Pain Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Diabetic Neuropathic Pain Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Diabetic Neuropathic Pain Drug Breakdown Data by Company
3.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Company (2020-2025)
3.1.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Company (2020-2025)
3.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Company (2020-2025)
3.2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company (2020-2025)
3.3 Global Diabetic Neuropathic Pain Drug Sale Price by Company
3.4 Key Manufacturers Diabetic Neuropathic Pain Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Diabetic Neuropathic Pain Drug Product Location Distribution
3.4.2 Players Diabetic Neuropathic Pain Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DIABETIC NEUROPATHIC PAIN DRUG BY GEOGRAPHIC REGION
4.1 World Historic Diabetic Neuropathic Pain Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Diabetic Neuropathic Pain Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Diabetic Neuropathic Pain Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Diabetic Neuropathic Pain Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Diabetic Neuropathic Pain Drug Sales Growth
4.4 APAC Diabetic Neuropathic Pain Drug Sales Growth
4.5 Europe Diabetic Neuropathic Pain Drug Sales Growth
4.6 Middle East & Africa Diabetic Neuropathic Pain Drug Sales Growth
5 AMERICAS
5.1 Americas Diabetic Neuropathic Pain Drug Sales by Country
5.1.1 Americas Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
5.1.2 Americas Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
5.2 Americas Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
5.3 Americas Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Diabetic Neuropathic Pain Drug Sales by Region
6.1.1 APAC Diabetic Neuropathic Pain Drug Sales by Region (2020-2025)
6.1.2 APAC Diabetic Neuropathic Pain Drug Revenue by Region (2020-2025)
6.2 APAC Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
6.3 APAC Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Diabetic Neuropathic Pain Drug by Country
7.1.1 Europe Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
7.1.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
7.2 Europe Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
7.3 Europe Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Diabetic Neuropathic Pain Drug by Country
8.1.1 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Diabetic Neuropathic Pain Drug
10.3 Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
10.4 Industry Chain Structure of Diabetic Neuropathic Pain Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Diabetic Neuropathic Pain Drug Distributors
11.3 Diabetic Neuropathic Pain Drug Customer
12 WORLD FORECAST REVIEW FOR DIABETIC NEUROPATHIC PAIN DRUG BY GEOGRAPHIC REGION
12.1 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Region
12.1.1 Global Diabetic Neuropathic Pain Drug Forecast by Region (2026-2031)
12.1.2 Global Diabetic Neuropathic Pain Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Diabetic Neuropathic Pain Drug Forecast by Type (2026-2031)
12.7 Global Diabetic Neuropathic Pain Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Information
13.1.2 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Astellas Pharma Inc. Main Business Overview
13.1.5 Astellas Pharma Inc. Latest Developments
13.2 AstraZeneca Plc
13.2.1 AstraZeneca Plc Company Information
13.2.2 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AstraZeneca Plc Main Business Overview
13.2.5 AstraZeneca Plc Latest Developments
13.3 BioDelivery Sciences International, Inc.
13.3.1 BioDelivery Sciences International, Inc. Company Information
13.3.2 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 BioDelivery Sciences International, Inc. Main Business Overview
13.3.5 BioDelivery Sciences International, Inc. Latest Developments
13.4 Boehringer Ingelheim GmbH
13.4.1 Boehringer Ingelheim GmbH Company Information
13.4.2 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Boehringer Ingelheim GmbH Main Business Overview
13.4.5 Boehringer Ingelheim GmbH Latest Developments
13.5 Daiichi Sankyo Company, Limited
13.5.1 Daiichi Sankyo Company, Limited Company Information
13.5.2 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Daiichi Sankyo Company, Limited Main Business Overview
13.5.5 Daiichi Sankyo Company, Limited Latest Developments
13.6 Dong-A Socio Group
13.6.1 Dong-A Socio Group Company Information
13.6.2 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Dong-A Socio Group Main Business Overview
13.6.5 Dong-A Socio Group Latest Developments
13.7 Eli Lilly and Company
13.7.1 Eli Lilly and Company Company Information
13.7.2 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Eli Lilly and Company Main Business Overview
13.7.5 Eli Lilly and Company Latest Developments
13.8 Glenmark Pharmaceuticals Ltd.
13.8.1 Glenmark Pharmaceuticals Ltd. Company Information
13.8.2 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Glenmark Pharmaceuticals Ltd. Main Business Overview
13.8.5 Glenmark Pharmaceuticals Ltd. Latest Developments
13.9 Hydra Biosciences, Inc.
13.9.1 Hydra Biosciences, Inc. Company Information
13.9.2 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Hydra Biosciences, Inc. Main Business Overview
13.9.5 Hydra Biosciences, Inc. Latest Developments
13.10 Immune Pharmaceuticals Inc.
13.10.1 Immune Pharmaceuticals Inc. Company Information
13.10.2 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Immune Pharmaceuticals Inc. Main Business Overview
13.10.5 Immune Pharmaceuticals Inc. Latest Developments
13.11 Laboratorios Del Dr. Esteve S.A.
13.11.1 Laboratorios Del Dr. Esteve S.A. Company Information
13.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Laboratorios Del Dr. Esteve S.A. Main Business Overview
13.11.5 Laboratorios Del Dr. Esteve S.A. Latest Developments
13.12 Lohocla Research Corporation
13.12.1 Lohocla Research Corporation Company Information
13.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Lohocla Research Corporation Main Business Overview
13.12.5 Lohocla Research Corporation Latest Developments
13.13 Mertiva AB
13.13.1 Mertiva AB Company Information
13.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Mertiva AB Main Business Overview
13.13.5 Mertiva AB Latest Developments
13.14 Novaremed
13.14.1 Novaremed Company Information
13.14.2 Novaremed Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Novaremed Main Business Overview
13.14.5 Novaremed Latest Developments
13.15 Pharmaleads
13.15.1 Pharmaleads Company Information
13.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Pharmaleads Main Business Overview
13.15.5 Pharmaleads Latest Developments
13.16 RAPID Pharmaceuticals AG
13.16.1 RAPID Pharmaceuticals AG Company Information
13.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 RAPID Pharmaceuticals AG Main Business Overview
13.16.5 RAPID Pharmaceuticals AG Latest Developments
13.17 Relmada Therapeutics, Inc.
13.17.1 Relmada Therapeutics, Inc. Company Information
13.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Relmada Therapeutics, Inc. Main Business Overview
13.17.5 Relmada Therapeutics, Inc. Latest Developments
13.18 Sphaera Pharma Pvt. Ltd.
13.18.1 Sphaera Pharma Pvt. Ltd. Company Information
13.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Sphaera Pharma Pvt. Ltd. Main Business Overview
13.18.5 Sphaera Pharma Pvt. Ltd. Latest Developments
13.19 Theravasc, Inc.
13.19.1 Theravasc, Inc. Company Information
13.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
13.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Theravasc, Inc. Main Business Overview
13.19.5 Theravasc, Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Diabetic Neuropathic Pain Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Diabetic Neuropathic Pain Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of AZD-5213
Table 4. Major Players of Clonidine Hydrochloride
Table 5. Major Players of Duloxetine Hydrochloride DR
Table 6. Major Players of E-52862
Table 7. Major Players ofFilgrastim
Table 8. Major Players of GERPOOI
Table 9. Major Players of GRC-17536
Table 10. Major Players of Others
Table 11. Global Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 12. Global Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Table 13. Global Diabetic Neuropathic Pain Drug Revenue byType (2020-2025) & ($ million)
Table 14. Global Diabetic Neuropathic Pain Drug Revenue Market Share byType (2020-2025)
Table 15. Global Diabetic Neuropathic Pain Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 16. Global Diabetic Neuropathic Pain Drug Sale by Application (2020-2025) & (K Pcs)
Table 17. Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2020-2025)
Table 18. Global Diabetic Neuropathic Pain Drug Revenue by Application (2020-2025) & ($ million)
Table 19. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2020-2025)
Table 20. Global Diabetic Neuropathic Pain Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 21. Global Diabetic Neuropathic Pain Drug Sales by Company (2020-2025) & (K Pcs)
Table 22. Global Diabetic Neuropathic Pain Drug Sales Market Share by Company (2020-2025)
Table 23. Global Diabetic Neuropathic Pain Drug Revenue by Company (2020-2025) & ($ millions)
Table 24. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company (2020-2025)
Table 25. Global Diabetic Neuropathic Pain Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 26. Key Manufacturers Diabetic Neuropathic Pain Drug Producing Area Distribution and Sales Area
Table 27. Players Diabetic Neuropathic Pain Drug Products Offered
Table 28. Diabetic Neuropathic Pain Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 29. New Products and Potential Entrants
Table 30. Market M&A Activity & Strategy
Table 31. Global Diabetic Neuropathic Pain Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 32. Global Diabetic Neuropathic Pain Drug Sales Market Share Geographic Region (2020-2025)
Table 33. Global Diabetic Neuropathic Pain Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 34. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Geographic Region (2020-2025)
Table 35. Global Diabetic Neuropathic Pain Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 36. Global Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2020-2025)
Table 37. Global Diabetic Neuropathic Pain Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 38. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Country/Region (2020-2025)
Table 39. Americas Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 40. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Country (2020-2025)
Table 41. Americas Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025) & ($ millions)
Table 42. Americas Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 43. Americas Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 44. APAC Diabetic Neuropathic Pain Drug Sales by Region (2020-2025) & (K Pcs)
Table 45. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Region (2020-2025)
Table 46. APAC Diabetic Neuropathic Pain Drug Revenue by Region (2020-2025) & ($ millions)
Table 47. APAC Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 48. APAC Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Europe Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Europe Diabetic Neuropathic Pain Drug Revenue by Country (2020-2025) & ($ millions)
Table 51. Europe Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Europe Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Country (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Table 55. Middle East & Africa Diabetic Neuropathic Pain Drug Sales byType (2020-2025) & (K Pcs)
Table 56. Middle East & Africa Diabetic Neuropathic Pain Drug Sales by Application (2020-2025) & (K Pcs)
Table 57. Key Market Drivers & Growth Opportunities of Diabetic Neuropathic Pain Drug
Table 58. Key Market Challenges & Risks of Diabetic Neuropathic Pain Drug
Table 59. Key IndustryTrends of Diabetic Neuropathic Pain Drug
Table 60. Diabetic Neuropathic Pain Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Diabetic Neuropathic Pain Drug Distributors List
Table 63. Diabetic Neuropathic Pain Drug Customer List
Table 64. Global Diabetic Neuropathic Pain Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. Global Diabetic Neuropathic Pain Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Americas Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Americas Diabetic Neuropathic Pain Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. APAC Diabetic Neuropathic Pain Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 69. APAC Diabetic Neuropathic Pain Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 70. Europe Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 71. Europe Diabetic Neuropathic Pain Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 72. Middle East & Africa Diabetic Neuropathic Pain Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 73. Middle East & Africa Diabetic Neuropathic Pain Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 74. Global Diabetic Neuropathic Pain Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 75. Global Diabetic Neuropathic Pain Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 76. Global Diabetic Neuropathic Pain Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 77. Global Diabetic Neuropathic Pain Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 78. Astellas Pharma Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 80. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 81. Astellas Pharma Inc. Main Business
Table 82. Astellas Pharma Inc. Latest Developments
Table 83. AstraZeneca Plc Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 85. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 86. AstraZeneca Plc Main Business
Table 87. AstraZeneca Plc Latest Developments
Table 88. BioDelivery Sciences International, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 90. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 91. BioDelivery Sciences International, Inc. Main Business
Table 92. BioDelivery Sciences International, Inc. Latest Developments
Table 93. Boehringer Ingelheim GmbH Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 95. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 96. Boehringer Ingelheim GmbH Main Business
Table 97. Boehringer Ingelheim GmbH Latest Developments
Table 98. Daiichi Sankyo Company, Limited Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 100. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 101. Daiichi Sankyo Company, Limited Main Business
Table 102. Daiichi Sankyo Company, Limited Latest Developments
Table 103. Dong-A Socio Group Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 105. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 106. Dong-A Socio Group Main Business
Table 107. Dong-A Socio Group Latest Developments
Table 108. Eli Lilly and Company Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 110. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 111. Eli Lilly and Company Main Business
Table 112. Eli Lilly and Company Latest Developments
Table 113. Glenmark Pharmaceuticals Ltd. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 115. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 116. Glenmark Pharmaceuticals Ltd. Main Business
Table 117. Glenmark Pharmaceuticals Ltd. Latest Developments
Table 118. Hydra Biosciences, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 120. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 121. Hydra Biosciences, Inc. Main Business
Table 122. Hydra Biosciences, Inc. Latest Developments
Table 123. Immune Pharmaceuticals Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 125. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 126. Immune Pharmaceuticals Inc. Main Business
Table 127. Immune Pharmaceuticals Inc. Latest Developments
Table 128. Laboratorios Del Dr. Esteve S.A. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 130. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 131. Laboratorios Del Dr. Esteve S.A. Main Business
Table 132. Laboratorios Del Dr. Esteve S.A. Latest Developments
Table 133. Lohocla Research Corporation Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 135. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 136. Lohocla Research Corporation Main Business
Table 137. Lohocla Research Corporation Latest Developments
Table 138. Mertiva AB Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 139. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 140. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 141. Mertiva AB Main Business
Table 142. Mertiva AB Latest Developments
Table 143. Novaremed Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 144. Novaremed Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 145. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 146. Novaremed Main Business
Table 147. Novaremed Latest Developments
Table 148. Pharmaleads Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 149. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 150. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 151. Pharmaleads Main Business
Table 152. Pharmaleads Latest Developments
Table 153. RAPID Pharmaceuticals AG Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 154. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 155. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 156. RAPID Pharmaceuticals AG Main Business
Table 157. RAPID Pharmaceuticals AG Latest Developments
Table 158. RelmadaTherapeutics, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 159. RelmadaTherapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 160. RelmadaTherapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 161. RelmadaTherapeutics, Inc. Main Business
Table 162. RelmadaTherapeutics, Inc. Latest Developments
Table 163. Sphaera Pharma Pvt. Ltd. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 164. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 165. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 166. Sphaera Pharma Pvt. Ltd. Main Business
Table 167. Sphaera Pharma Pvt. Ltd. Latest Developments
Table 168.Theravasc, Inc. Basic Information, Diabetic Neuropathic Pain Drug Manufacturing Base, Sales Area and Its Competitors
Table 169.Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolios and Specifications
Table 170.Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 171.Theravasc, Inc. Main Business
Table 172.Theravasc, Inc. Latest Developments
LIST OFFIGURES
Figure 1. Picture of Diabetic Neuropathic Pain Drug
Figure 2. Diabetic Neuropathic Pain Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Diabetic Neuropathic Pain Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Diabetic Neuropathic Pain Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Diabetic Neuropathic Pain Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2024)
Figure 10. Diabetic Neuropathic Pain Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of AZD-5213
Figure 12. Product Picture of Clonidine Hydrochloride
Figure 13. Product Picture of Duloxetine Hydrochloride DR
Figure 14. Product Picture of E-52862
Figure 15. Product Picture ofFilgrastim
Figure 16. Product Picture of GERPOOI
Figure 17. Product Picture of GRC-17536
Figure 18. Product Picture of Others
Figure 19. Global Diabetic Neuropathic Pain Drug Sales Market Share byType in 2025
Figure 20. Global Diabetic Neuropathic Pain Drug Revenue Market Share byType (2020-2025)
Figure 21. Diabetic Neuropathic Pain Drug Consumed in Clinic
Figure 22. Global Diabetic Neuropathic Pain Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Diabetic Neuropathic Pain Drug Consumed in Hospital
Figure 24. Global Diabetic Neuropathic Pain Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 25. Diabetic Neuropathic Pain Drug Consumed in Others
Figure 26. Global Diabetic Neuropathic Pain Drug Market: Others (2020-2025) & (K Pcs)
Figure 27. Global Diabetic Neuropathic Pain Drug Sale Market Share by Application (2024)
Figure 28. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application in 2025
Figure 29. Diabetic Neuropathic Pain Drug Sales by Company in 2025 (K Pcs)
Figure 30. Global Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2025
Figure 31. Diabetic Neuropathic Pain Drug Revenue by Company in 2025 ($ millions)
Figure 32. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Company in 2025
Figure 33. Global Diabetic Neuropathic Pain Drug Sales Market Share by Geographic Region (2020-2025)
Figure 34. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Geographic Region in 2025
Figure 35. Americas Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 36. Americas Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 37. APAC Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 38. APAC Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 39. Europe Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 40. Europe Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 41. Middle East & Africa Diabetic Neuropathic Pain Drug Sales 2020-2025 (K Pcs)
Figure 42. Middle East & Africa Diabetic Neuropathic Pain Drug Revenue 2020-2025 ($ millions)
Figure 43. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2025
Figure 44. Americas Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Figure 45. Americas Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 46. Americas Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 47. United States Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Canada Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. Mexico Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Brazil Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Region in 2025
Figure 52. APAC Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2020-2025)
Figure 53. APAC Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 54. APAC Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 55. China Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Japan Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. South Korea Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Southeast Asia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. India Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Australia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. ChinaTaiwan Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country in 2025
Figure 63. Europe Diabetic Neuropathic Pain Drug Revenue Market Share by Country (2020-2025)
Figure 64. Europe Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 65. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 66. Germany Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 67.France Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. UK Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Italy Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Russia Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2020-2025)
Figure 72. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share byType (2020-2025)
Figure 73. Middle East & Africa Diabetic Neuropathic Pain Drug Sales Market Share by Application (2020-2025)
Figure 74. Egypt Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. South Africa Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Israel Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 77.Turkey Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 78. GCC Countries Diabetic Neuropathic Pain Drug Revenue Growth 2020-2025 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Diabetic Neuropathic Pain Drug in 2025
Figure 80. Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
Figure 81. Industry Chain Structure of Diabetic Neuropathic Pain Drug
Figure 82. Channels of Distribution
Figure 83. Global Diabetic Neuropathic Pain Drug Sales MarketForecast by Region (2026-2031)
Figure 84. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 85. Global Diabetic Neuropathic Pain Drug Sales Market ShareForecast byType (2026-2031)
Figure 86. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast byType (2026-2031)
Figure 87. Global Diabetic Neuropathic Pain Drug Sales Market ShareForecast by Application (2026-2031)
Figure 88. Global Diabetic Neuropathic Pain Drug Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Waveguide Couplers Market Growth 2025-2031
US$ 3,660.00
October 2026
132 pages
Global Miniature Torque Sensors Market Growth 2025-2031
US$ 3,660.00
August 2025
173 pages
Global Digital Marketing Analytics System Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
101 pages
Global Low Voltage Fault Current Limiter Market Growth 2026-2032
US$ 3,660.00
June 2026
126 pages
Global Band Pass Filters Market Growth 2025-2031
US$ 3,660.00
October 2026
140 pages
